File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Efficacy of current antiemetic treatments for preventing delayed chemotherapy-induced nausea and vomiting: A meta-analysis of randomized controlled trials

TitleEfficacy of current antiemetic treatments for preventing delayed chemotherapy-induced nausea and vomiting: A meta-analysis of randomized controlled trials
Authors
Keywords5-HT3 receptor antagonist
Antiemetic
Chemotherapy
Dexamethasone
Meta-analysis
Metoclopramide
Issue Date2004
PublisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/10601333.asp
Citation
Clinical Research And Regulatory Affairs, 2004, v. 21 n. 3-4, p. 191-212 How to Cite?
AbstractTreatments consisting of dexamethasone with a 5-HT3 receptor antagonist (5-HT3RA) or metoclopramide are commonly used for controlling delayed chemotherapy-induced nausea and vomiting (CINV). We evaluated systematically the efficacy of these treatments for preventing delayed CINV. We undertook a meta-analysis of studies that met the following entry criteria: randomized clinical trials comparing dexamethasone and a 5-HT 3RA versus dexamethasone alone or dexamethasone with metoclopramide for preventing delayed CINV; same prophylactic treatment must be used for acute CINV. A comprehensive literature search was conducted. Of 54 potentially useful studies, eight reports met the criteria and were analyzed. The overall total protection from delayed CINV was similar between patients receiving a 5-HT 3RA combined with dexamethasone (53.2%, 454/853) and dexamethasone alone (53.3%, 450/844), yielding a relative risk (RR) of 1.03 (95% CI 0.97-1.09). Similar efficacy between the two treatment groups was also observed for preventing delayed nausea [RR 1.03 (95% CI 0.98-1.09)] and vomiting [RR 1.03 (95% CI 0.99-1.07)]. No significant difference in the efficacy of preventing delayed CINV was observed between patients receiving dexamethasone combined with either a 5-HT3RA or metoclopramide. We conclude that treatments consisting of dexamethasone and a 5-HT3RA or metoclopramide have similar efficacy to dexamethasone alone for preventing delayed CINV. Copyright © 2004 by Taylor & Francis Inc.
Persistent Identifierhttp://hdl.handle.net/10722/87554
ISSN
2003 Impact Factor: 0.03
2015 SCImago Journal Rankings: 0.105
References

 

DC FieldValueLanguage
dc.contributor.authorJia, QHen_HK
dc.contributor.authorGe, FZen_HK
dc.contributor.authorChan, GCFen_HK
dc.contributor.authorKarlberg, Jen_HK
dc.contributor.authorShiu, KLen_HK
dc.contributor.authorWong, BCYen_HK
dc.date.accessioned2010-09-06T09:31:21Z-
dc.date.available2010-09-06T09:31:21Z-
dc.date.issued2004en_HK
dc.identifier.citationClinical Research And Regulatory Affairs, 2004, v. 21 n. 3-4, p. 191-212en_HK
dc.identifier.issn1060-1333en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87554-
dc.description.abstractTreatments consisting of dexamethasone with a 5-HT3 receptor antagonist (5-HT3RA) or metoclopramide are commonly used for controlling delayed chemotherapy-induced nausea and vomiting (CINV). We evaluated systematically the efficacy of these treatments for preventing delayed CINV. We undertook a meta-analysis of studies that met the following entry criteria: randomized clinical trials comparing dexamethasone and a 5-HT 3RA versus dexamethasone alone or dexamethasone with metoclopramide for preventing delayed CINV; same prophylactic treatment must be used for acute CINV. A comprehensive literature search was conducted. Of 54 potentially useful studies, eight reports met the criteria and were analyzed. The overall total protection from delayed CINV was similar between patients receiving a 5-HT 3RA combined with dexamethasone (53.2%, 454/853) and dexamethasone alone (53.3%, 450/844), yielding a relative risk (RR) of 1.03 (95% CI 0.97-1.09). Similar efficacy between the two treatment groups was also observed for preventing delayed nausea [RR 1.03 (95% CI 0.98-1.09)] and vomiting [RR 1.03 (95% CI 0.99-1.07)]. No significant difference in the efficacy of preventing delayed CINV was observed between patients receiving dexamethasone combined with either a 5-HT3RA or metoclopramide. We conclude that treatments consisting of dexamethasone and a 5-HT3RA or metoclopramide have similar efficacy to dexamethasone alone for preventing delayed CINV. Copyright © 2004 by Taylor & Francis Inc.en_HK
dc.languageengen_HK
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/10601333.aspen_HK
dc.relation.ispartofClinical Research and Regulatory Affairsen_HK
dc.rightsClinical Research and Regulatory Affairs. Copyright © Informa Healthcare.en_HK
dc.subject5-HT3 receptor antagonisten_HK
dc.subjectAntiemeticen_HK
dc.subjectChemotherapyen_HK
dc.subjectDexamethasoneen_HK
dc.subjectMeta-analysisen_HK
dc.subjectMetoclopramideen_HK
dc.titleEfficacy of current antiemetic treatments for preventing delayed chemotherapy-induced nausea and vomiting: A meta-analysis of randomized controlled trialsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1060-1333&volume=21 &issue=3&4&spage=191&epage=212&date=2004&atitle=Efficacy+of+Current+Antiemetic+Treatments+for+Preventing+Delayed+Chemotherapy-Induced+Nausea+and+Vomiting:+A+Meta-Analysis+of+Randomized+Controlled+Trialsen_HK
dc.identifier.emailChan, GCF: gcfchan@hku.hken_HK
dc.identifier.emailKarlberg, J: jpekarl@hkucc.hku.hken_HK
dc.identifier.emailWong, BCY: bcywong@hku.hken_HK
dc.identifier.authorityChan, GCF=rp00431en_HK
dc.identifier.authorityKarlberg, J=rp00400en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1081/CRP-200049997en_HK
dc.identifier.scopuseid_2-s2.0-15444379255en_HK
dc.identifier.hkuros97502en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-15444379255&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume21en_HK
dc.identifier.issue3-4en_HK
dc.identifier.spage191en_HK
dc.identifier.epage212en_HK
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridJia, QH=7403635051en_HK
dc.identifier.scopusauthoridGe, FZ=8244664100en_HK
dc.identifier.scopusauthoridChan, GCF=16160154400en_HK
dc.identifier.scopusauthoridKarlberg, J=7005218406en_HK
dc.identifier.scopusauthoridShiu, KL=36965233000en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats